Product Code: RP-ID-10246012 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10246012
Market Overview:
Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024) 2022-2030
"The global market for invasive fungal infections is estimated to be ~USD 12 billion by the end of 2021 and is forecasted to mark a CAGR of ~2% over the period 2022-2030. The HIV/AIDS population has increased thanks to the discovery and development of drugs and facilities that intensive care units provide to affected people. surgical intervention. The rise of chemotherapy, antibiotic use and global economic growth are accelerating an aggressive market for fungal infections.
The introduction of advanced drugs is already creative, as it directly improves the health and extends life expectancy of vaccinated patients. The market for invasive fungal infections is mainly driven by high demand for low-cost pipeline products, increasing use of large-scale antibiotics, fungal resistance to various drugs, and low-cost pharmaceutical choices. future. It has a longer duration of action than conventional drugs.
Several companies provide a variety of antibiotics, these antibiotics reduce the resistance of various drugs, thereby increasing the incidence of invasive fungal infections. In addition, leading invasive antifungal manufacturers in various regions have increased their investment.
These manufacturers have a demand for low-cost and effective products. After the government conducts solid organ transplantation through various government-driven awareness programs, it focuses on educating people in the ICU. The care provided during hospitalization, running with the goal of eradicating the disease, is expected to stimulate market growth during the forecast period.
Several companies provide various antibiotics, which reduce the resistance of various drugs, thereby increasing the incidence of invasive fungal infections. In addition, leading invasive antifungal manufacturers in various regions have increased their investment. These manufacturers have a demand for low-cost and effective products. After the government conducts solid organ transplantation through various government-driven awareness programs, it focuses on educating people in the ICU. The care provided during hospitalization, running with the goal of eradicating the disease, is expected to stimulate market growth during the forecast period.
REPORT SCOPE :
This report analyzes the global market for invasive fungal infections (candidiasis and invasive candidiasis, intra-abdominal candidiasis (candida peritonitis), cryptococcal meningitis, disseminated histoplasmosis, Acute lung histoplasmosis, invasive aspergillosis, infectious candidiasis, infectious candidiasis, and other infectious candidiasis markets) Invasive fungal infections have been classified by region (North America, Europe, Asia Pacific, ROW) And countries (the United States, Canada, Germany, France, the United Kingdom, Spain, China, South Korea, Japan, India) have been analyzed and the report has been presented through the framework of SWOT, Porter and market attractiveness charts.
A chart of market attractiveness by disease and by region has been provided. In addition, the report also discusses top industry opportunities, trends, drivers and challenges. The report analyzes in detail the drug pipeline that is being developed to treat the problem of invasive fungal infections. The report tracks competitive development, market share analysis, strategy and new product development. The companies analyzed in the report include Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, Bayer, Abott, Merck, Astellas, F2G-The Rare Fungal Disease Company, Scynexis Inc. The report is globally invasive Analyze the fungal infection market with a historical period of 2014-2018 and a forecast period of 2022-2030.
MAIN TARGET AUDIENCE :
pharmaceutical companies, consulting companies, medical professionals, regulatory agencies"
Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abott, Merck & Co., Astellas Pharma Inc., F2G – The Rare Fungal Disease Company, Scynexis Inc
Related Reports
Proof of Quality & Reliability
